Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer

Activation of CDK2 in triple negative breast cancer (TNBC) can contribute to non-canonical phosphorylation of a TGFβ signaling component, Smad3, promoting cell proliferation and migration. Inhibition of CDK2 was shown to decrease breast cancer oncogenesis. Eribulin chemotherapy was used effectively...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Rao, Shreyas S., Stoehr, Jenna, Dokic, Danijela, Wan, Lei, Decker, Joseph T., Konopka, Kristine, Thomas, Alexandra L., Wu, Jia, Kaklamani, Virginia G., Shea, Lonnie D., Jeruss, Jacqueline S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2017
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5663565/
https://ncbi.nlm.nih.gov/pubmed/29137393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20202
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge